Security key
98420N105
Xenon Pharmaceuticals Inc. - Common Stock (XENE)
CUSIP: 98420N105
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 84,413,479
- Total 13F value
- $3,783,396,815
- Share change
- -594,096
- Put/Call ratio
- 192%
- SEC-reported price per share
- $44.82
- Number of holders
- 245
- Value change
- -$19,907,308
- Number of buys
- 125
- Number of sells
- 95
- Shares outstanding
- 95,032,800
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
245
Top holders
10
XENE full security history
Ownership snapshot
Full 13F holder table
Xenon Pharmaceuticals Inc. SEC filings
Xenon Pharmaceuticals Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of XENE - Xenon Pharmaceuticals Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
31 Dec 2025
13F
13D/G
Lead comparable stake: 6.2%
13D/G row: BlackRock, Inc.
Showing 1-6 of 15 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 6.2%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
6.2%
DRIEHAUS CAPITAL MANAGEMENT LLC
4.9%
FMR LLC
9.4%
Avoro Capital Advisors LLC
5.7%
Janus Henderson Group Ltd.
4.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
6.2%
from 13D/G
|
$191,553,697
4,770,951 shares
|
— | 30 Sep 2025 |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13D/G
13F
Company
|
4.9%
|
$255,350,473
4,491,653 shares
|
$0 | 31 Dec 2025 |
| FMR LLC |
13F
Company
|
9.4%
|
$358,094,116
8,918,907 shares
|
— | 30 Sep 2025 |
| Avoro Capital Advisors LLC |
13F
Company
|
5.7%
|
$216,810,000
5,400,000 shares
|
— | 30 Sep 2025 |
| Janus Henderson Group Ltd. |
13F
Company
|
4.2%
|
$158,311,659
3,943,885 shares
|
— | 30 Sep 2025 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
Company
|
3.8%
|
$144,935,758
3,609,857 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
245
Shares
84,413,479
Rows available
245
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
218
Q4 2025 holders
245
Holder diff
27
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|